European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group listed 15 topics of concrete clinical scenarios and formulated as practical answers as possible based on available evidence. The 15 topics are: (1) Practical start-up and follow-up scheme for…

• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• BS
  Boston Scientific Corporation
• EC
  European Commission
• BH
  Bayer HealthCare
• DF
  Deutsche Forschungsgemeinschaft
• FL
  Fondation Leducq
• BF
  Bundesministerium für Bildung und Forschung
• D
  Daiichi-Sankyo
• DG
  Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
• S
  Servier
• MG
  Menarini Group
• SJ
  St. Jude Medical
• MS
  Merck Sharp and Dohme
• BW
  Biosense Webster
• DS
  Daiichi Sankyo Europe
• AP
  Actelion Pharmaceuticals